Flag of the European Union EU Clinical Trials Register Help

Clinical trials for ulcerative colitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    412 result(s) found for: ulcerative colitis. Displaying page 21 of 21.
    «« First « Previous 13  14  15  16  17  18  19  20  21 
    EudraCT Number: 2013-005013-13 Sponsor Protocol Number: SB5-G31-RA Start Date*: 2014-04-03
    Sponsor Name:Samsung Bioepis Co., Ltd.
    Full Title: A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Immunogenicity of SB5 Compared to Humira® in Subjects wit...
    Medical condition: Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy. The intended use of SB5 is rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA), adult Cr...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-006532-21 Sponsor Protocol Number: 40054-22062 Start Date*: 2008-10-27
    Sponsor Name:EORTC
    Full Title: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer (PETACC-6)
    Medical condition: locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001086-41 Sponsor Protocol Number: UKM10_0014 Start Date*: 2012-02-28
    Sponsor Name:University Hospital of Muenster
    Full Title: A randomized, placebo-controlled, multi-center phase I/II trial to assess the safety and efficacy of nintedanib (BIBF 1120) added to low-dose cytarabine in elderly patients with AML unfit for an in...
    Medical condition: untreated acute myeloid leukemia patients unfit for an intensive treatment
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001290-23 Sponsor Protocol Number: C4591024 Start Date*: Information not available in EudraCT
    Sponsor Name:BioNTech SE
    Full Title: A PHASE 2b, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VACCINE CANDIDATE BNT162b2 IN IMMUNOCOMPROMISED PARTICIPANTS ≥2 YEARS OF AGE
    Medical condition: Protection against COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: View results
    EudraCT Number: 2022-002695-37 Sponsor Protocol Number: CLIN-60190-453 Start Date*: 2023-04-27
    Sponsor Name:Ipsen Bioscience, Inc.
    Full Title: A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open-Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants with Primary ...
    Medical condition: Adults patients with Primary Sclerosing Cholangitis (PSC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10036732 Primary sclerosing cholangitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001471-36 Sponsor Protocol Number: PrimeRT-2018 Start Date*: 2020-10-05
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. The University of Glasgow
    Full Title: Priming the Tumour MicroEnvironment for Effective Treatment with Immunotherapy in Locally Advanced Rectal Cancer: A Phase II trial of Durvulamab in Combination with Extended Neoadjuvant Regimens i...
    Medical condition: Rectal Cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038038 Rectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-005999-36 Sponsor Protocol Number: HZNP-TEP-402 Start Date*: 2022-05-24
    Sponsor Name:Horizon Therapeutics U.S.A., Inc.
    Full Title: A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients with Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durat...
    Medical condition: Thyroid Eye Disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020003-73 Sponsor Protocol Number: A3921079 Start Date*: 2011-03-31
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, 10017 USA
    Full Title: A PHASE 3, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE...
    Medical condition: Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-002452-87 Sponsor Protocol Number: P-Monofer-IBD-03 Start Date*: 2017-09-11
    Sponsor Name:Pharmacosmos A/S
    Full Title: A randomized, double-blinded, comparative trial comparing the incidence of hypophosphatemia in relation to repeated treatment courses of iron isomaltoside and ferric carboxymaltose in subjects with...
    Medical condition: Iron deficiency anemia in subject with inflammatory bowel disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    20.0 10005329 - Blood and lymphatic system disorders 10079322 Anaemia of chronic inflammation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022209-16 Sponsor Protocol Number: ICON8 Start Date*: 2011-04-08
    Sponsor Name:University College London
    Full Title: ICON8 Trials Programme ICON8: An international phase 3 randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as ...
    Medical condition: ICON8: Newly diagnosed high risk early stage (FIGO stage IC/IIA, grade 3 or clear cell histology only) or advanced stage (FIGO stage IIB-IV, all grades and all histological types) epithelial ovaria...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052171 Peritoneal carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-003477-61 Sponsor Protocol Number: 20210098 Start Date*: 2022-07-13
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Canc...
    Medical condition: Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    23.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10084227 Gastroesophageal junction cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned) BG (Trial now transitioned) FR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003367-19 Sponsor Protocol Number: NUC-5/PSC Start Date*: 2017-09-28
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis
    Medical condition: Primary Sclerosing Cholangitis (PSC) is a slowly progressing chronic cholestatic liver disease of assumed autoimmune, but finally unidentified etiology, characterized by a chronic inflammatory and ...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10036732 Primary sclerosing cholangitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) LT (Completed) FI (Trial now transitioned) CZ (Prematurely Ended) BE (Completed) DK (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) SE (Completed) NO (Trial now transitioned) PL (Trial now transitioned) IE (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 13  14  15  16  17  18  19  20  21 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 05:01:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA